Table 4.
Comparison of dosimetry results (ED) for different PET tracers including the current study with [18F]fluspidine.
| Tracer | Target Organ | Clinical (μSv/MBq) | Preclinical (μSv/MBq) | Reference |
|---|---|---|---|---|
| (S)-(−)-[18F]fluspidine | brain, tumor | 21.0 | 12.9 (mouse, imaging) 16.7 (mouse, harvesting) | this study |
| (R)-(+)-[18F]fluspidine | brain, tumor | n.a. | 14.0 (mouse, imaging) 18.4 (mouse, harvesting) | this study |
| (−)-[18F]flubatine (formerly [18F]NCFHEB) | brain | 23.4 | 12.5 (mouse) 14.7 (piglet, imaging) | [24] |
| (+)-[18F]flubatine | brain | 23.0 | 12.1 (mouse, imaging) 14.3 (piglets, imaging) | [25] |
| [18F]FEDAA1106 | brain | 36 | 21.0 (male mouse) 26.0 (female mouse) | [28] |
| [18F]FET | brain tumor | 16.5 | 9.0 | [29,30] |
| 2-[18F]F-A85380 | brain | 19.4 | n.a. | [31] |
| [18F]FDG | multiple | 19.0 | n.a. | [32] |